Disease Info Card

Malignant Hyperpyrexia Due To Anesthesia

Information about Malignant Hyperpyrexia Due To Anesthesia: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Malignant Hyperpyrexia Due To Anesthesia

Most recent studies have shown that Malignant Hyperpyrexia Due To Anesthesia shares some biological mechanisms with acidosis, cardiac-arrest, cardiac-arrhythmia, central-core-myopathy-(disorder), dystrophy, hyperpyrexia, intraoperative-complications, malignant-paraganglionic-neoplasm, muscle-contracture, muscle-hypotonia, muscle-rigidity, muscle-twitch, muscular-dystrophy, myopathy, neuroleptic-malignant-syndrome, neuromuscular-diseases, rhabdomyolysis, spasm, swine-diseases, weakness.

Among the many pathways, these few ones have gauged particular interests from scientists studying Malignant Hyperpyrexia Due To Anesthesia, and have been seen in publications frequently: Anaphylaxis, Cell Death, Coagulation, Diuresis, Excretion, Glycolysis, Heat Dissipation, Hypersensitivity, Localization, Membrane Depolarization, Muscle Contraction, Oxidative Phosphorylation, Pathogenesis, Reflex, Regeneration, Response To Caffeine, Secretion, Skeletal Muscle Contraction, Transport, Vasoconstriction

Quite a number of genes have been found to play important roles in Malignant Hyperpyrexia Due To Anesthesia, such as BCHE, C2, CACNA1S, CALM1, CALM2, CALM3, CHKA, CHKB, DMD, GPI, HAL, MB, PIK3C2A, RUNX2, RYR1, RYR2, SCTR, SNCG. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.